Stock exchange news | Navamedic

Read the latest news directly from the market.

Navamedic ASA: Q2 and first half 2022 financial results

“We are pleased to report record-high revenues and continued strengthening of our profits and cash flow in the second quarter. Read more

Navamedic ASA: Invitation to 2022 second quarter presentation

Oslo, August 9, 2022 - Navamedic ASA (OSE: Nava) will be presenting its second quarter 2022 results on Friday, August Read more

Navamedic ASA – Exclusive agreement with Vectans Pharma for the unique cold sore treatment product Sitavig®

Oslo, 4 August 2022 - Navamedic has signed an agreement with the French pharmaceutical company Vectans Pharma, which gives Read more

Navamedic ASA: Trading Update

As the company’s preliminary consolidated financial results for the second quarter of 2022 (and hence first half of the year) Read more

Navamedic ASA: Minutes of Annual General Meeting

Oslo, 2 June 2022: The Annual General Meeting of Navamedic ASA was held today at 13:00 CEST. All items on Read more

Navamedic ASA completes acquisition of Impolin AB and issues consideration shares

Oslo, 1 June 2022 - Navamedic ASA ("Navamedic" or the "Company") (OSE: NAVA) today announces that it has completed the Read more

Navamedic ASA: Q1 2022 financial results

Oslo, 10 May 2022 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products Read more

Navamedic ASA acquires Impolin AB and bolsters its product portfolio

The proposed acquisition reinforces Navamedic’s position in the market for obesity treatment The acquired portfolio enables Navamedic to support patients Read more

Subscribe to stock exhange news